Femasys Inc (FEMY)

$0.44 +0.02 (5.32%)
Market Cap 26.52M
Revenue (ttm) 1.63M
Net Income (ttm) -18.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,154.60%
Debt to Equity Ratio 0.02
Volume 274,000
Avg Vol 583,148
Day's Range N/A - N/A
Shares Out 60.39M
Stochastic %K 50%
Beta -2.28
Analysts Strong Sell
Price Target $3.50

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 770 500 3910
Fax: 404 581 5903
Address:
3950 Johns Creek Court, Suite 100, Suwanee, United States
TripTrap
TripTrap Apr. 5 at 2:52 PM
$FEMY Happy Easter to all that celebrate this holiday. I know I have been saying it for a while, but I do believe good things are coming to us that are patient here. ♥️✝️🐇
0 · Reply
VintageVince
VintageVince Apr. 5 at 7:27 AM
$FEMY : On March 31, 2026, Femasys confirmed that patient enrollment is officially underway for its FINALE pivotal clinical trial. This is the final major step toward seeking FDA approval for its non-surgical permanent birth control solution.
0 · Reply
SagaSeeker
SagaSeeker Apr. 3 at 1:08 AM
$YYAI and $FEMY both multiday potential runners.
0 · Reply
4RiskyBusiness4
4RiskyBusiness4 Apr. 2 at 8:07 PM
$FEMY A new CFO like that tightens the ourse strings and drives cost efficieneices. Their fresh eyes mean even better earnings. Cant wait!
1 · Reply
StarlinePalaceTrades
StarlinePalaceTrades Apr. 2 at 5:37 PM
$FEMY
0 · Reply
Alican1994
Alican1994 Apr. 2 at 1:27 PM
$FEMY Suena campana
0 · Reply
Alican1994
Alican1994 Apr. 2 at 12:37 PM
$FEMY
0 · Reply
TripTrap
TripTrap Apr. 2 at 1:41 AM
$FEMY just hired John Canning as COO - 25+ years at Terumo/Medtronic. This is interesting timing... You don't hire an expensive COO with serious MedTech experience unless you're preparing for growth, not just surviving. Companies cutting costs don't add C-level executives. His background: global operations, manufacturing scale-up, device commercialization. Exactly what you'd need for rolling out FemBloc/FemaSeed worldwide. Plus 150K stock options at today's price ($0.48) - he clearly believes there's upside ahead. Coming right after strong earnings showing European traction and with the FDA trial enrolling... feels like management is positioning for the next phase rather than crisis mode.
1 · Reply
TripTrap
TripTrap Apr. 1 at 10:15 PM
$FEMY Alert to newcomers - Mirto used to be a heavy long on FEMY and has now turned into one of the main bashers on our board here. Admittedly, FEMY has been quite frustrating, and it is only for patient investors, which he is not. He is now aggressively, bashing it and suspect he has a large short on the stock right now. Why else would someone waste so much time posting on this board? He trades based on emotions, not research. He doesn’t like me and others here because we confront him with facts. He does not like that, especially me, because I am quite vocal on the board. Please look back at my posts to get a good idea of what FEMY is all about, covering both fundamentals and technicals. It takes time to build a company that will completely disrupt women’s reproductive healthcare. I think the rewards will be outstanding someday. Do your own research and ask if you have any questions. 
0 · Reply
Mirto
Mirto Apr. 1 at 8:03 PM
$FEMY welcome aboard to another washed up top heavy officer. Kathy has only pissed thru 141,000,000$ and counting with this scam. Resign already, your leadership is sheer and utter failure. You are a failure. Go far away, take the other mooching sponges with you and let the men handle things.
3 · Reply
Latest News on FEMY
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Mar 31, 2026, 4:05 PM EDT - 4 days ago

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2026, 5:26 PM EST - 5 weeks ago

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Feb 23, 2026, 9:00 AM EST - 5 weeks ago

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Jan 13, 2026, 9:00 AM EST - 2 months ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Dec 18, 2025, 9:15 AM EST - 3 months ago

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Nov 25, 2025, 9:15 AM EST - 4 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Nov 3, 2025, 8:30 AM EST - 5 months ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Oct 16, 2025, 9:00 AM EDT - 6 months ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 11, 2025, 9:00 AM EDT - 7 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Sep 8, 2025, 9:00 AM EDT - 7 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 25, 2025, 11:44 PM EDT - 7 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Femasys Announces Second Quarter Financial Results for 2025

Aug 8, 2025, 4:05 PM EDT - 8 months ago

Femasys Announces Second Quarter Financial Results for 2025

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Aug 6, 2025, 9:00 AM EDT - 8 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jul 1, 2025, 9:00 AM EDT - 9 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 25, 2025, 9:00 AM EDT - 10 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 17, 2025, 9:00 AM EDT - 10 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Jun 11, 2025, 9:00 AM EDT - 10 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 29, 2025, 4:23 PM EDT - 11 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025, 5:01 PM EDT - 11 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 19, 2025, 9:20 AM EDT - 1 year ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 18, 2025, 9:00 AM EDT - 1 year ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 25, 2025, 9:20 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Feb 11, 2025, 9:00 AM EST - 1 year ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 30, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Jan 16, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 17, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 16, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 9, 2024, 8:30 AM EDT - 2 years ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

May 7, 2024, 8:30 AM EDT - 2 years ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Apr 18, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 20, 2024, 8:15 AM EDT - 2 years ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Mar 6, 2024, 9:00 AM EST - 2 years ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

TripTrap
TripTrap Apr. 5 at 2:52 PM
$FEMY Happy Easter to all that celebrate this holiday. I know I have been saying it for a while, but I do believe good things are coming to us that are patient here. ♥️✝️🐇
0 · Reply
VintageVince
VintageVince Apr. 5 at 7:27 AM
$FEMY : On March 31, 2026, Femasys confirmed that patient enrollment is officially underway for its FINALE pivotal clinical trial. This is the final major step toward seeking FDA approval for its non-surgical permanent birth control solution.
0 · Reply
SagaSeeker
SagaSeeker Apr. 3 at 1:08 AM
$YYAI and $FEMY both multiday potential runners.
0 · Reply
4RiskyBusiness4
4RiskyBusiness4 Apr. 2 at 8:07 PM
$FEMY A new CFO like that tightens the ourse strings and drives cost efficieneices. Their fresh eyes mean even better earnings. Cant wait!
1 · Reply
StarlinePalaceTrades
StarlinePalaceTrades Apr. 2 at 5:37 PM
$FEMY
0 · Reply
Alican1994
Alican1994 Apr. 2 at 1:27 PM
$FEMY Suena campana
0 · Reply
Alican1994
Alican1994 Apr. 2 at 12:37 PM
$FEMY
0 · Reply
TripTrap
TripTrap Apr. 2 at 1:41 AM
$FEMY just hired John Canning as COO - 25+ years at Terumo/Medtronic. This is interesting timing... You don't hire an expensive COO with serious MedTech experience unless you're preparing for growth, not just surviving. Companies cutting costs don't add C-level executives. His background: global operations, manufacturing scale-up, device commercialization. Exactly what you'd need for rolling out FemBloc/FemaSeed worldwide. Plus 150K stock options at today's price ($0.48) - he clearly believes there's upside ahead. Coming right after strong earnings showing European traction and with the FDA trial enrolling... feels like management is positioning for the next phase rather than crisis mode.
1 · Reply
TripTrap
TripTrap Apr. 1 at 10:15 PM
$FEMY Alert to newcomers - Mirto used to be a heavy long on FEMY and has now turned into one of the main bashers on our board here. Admittedly, FEMY has been quite frustrating, and it is only for patient investors, which he is not. He is now aggressively, bashing it and suspect he has a large short on the stock right now. Why else would someone waste so much time posting on this board? He trades based on emotions, not research. He doesn’t like me and others here because we confront him with facts. He does not like that, especially me, because I am quite vocal on the board. Please look back at my posts to get a good idea of what FEMY is all about, covering both fundamentals and technicals. It takes time to build a company that will completely disrupt women’s reproductive healthcare. I think the rewards will be outstanding someday. Do your own research and ask if you have any questions. 
0 · Reply
Mirto
Mirto Apr. 1 at 8:03 PM
$FEMY welcome aboard to another washed up top heavy officer. Kathy has only pissed thru 141,000,000$ and counting with this scam. Resign already, your leadership is sheer and utter failure. You are a failure. Go far away, take the other mooching sponges with you and let the men handle things.
3 · Reply
focafoca99
focafoca99 Apr. 1 at 7:25 PM
$FEMY brought in John Canning as COO to tighten execution as it pushes commercialization of FemBloc and FemaSeed.
0 · Reply
Severian1
Severian1 Apr. 1 at 3:59 PM
$FEMY Canning seems legit
1 · Reply
Agge11
Agge11 Apr. 1 at 2:33 PM
$FEMY https://finance.yahoo.com/sectors/healthcare/articles/femasys-announces-financial-results-ended-200500659.html
0 · Reply
Alican1994
Alican1994 Apr. 1 at 2:31 PM
$FEMY
0 · Reply
Agge11
Agge11 Apr. 1 at 2:29 PM
$FEMY 👇👇👇
0 · Reply
Agge11
Agge11 Apr. 1 at 2:24 PM
$FEMY https://finance.yahoo.com/sectors/healthcare/articles/femasys-appoints-john-canning-chief-130000849.html
0 · Reply
Bluesir
Bluesir Apr. 1 at 1:38 PM
$FEMY one good reason:they are finalizing new dealers agreements and needs to be ready.
0 · Reply
beart00th
beart00th Apr. 1 at 1:20 PM
$FEMY Inventory jumped to $5.74M from $3.05M Why would they increase inventory?🧐
0 · Reply
ZeroJobZeroProblem
ZeroJobZeroProblem Apr. 1 at 1:09 PM
$FEMY welcome John Canning… this proves they are continuing the growth pattern in order to advance.
1 · Reply
JS10gamer007
JS10gamer007 Apr. 1 at 12:59 PM
$FEMY can we see level 2 please
3 · Reply
4RiskyBusiness4
4RiskyBusiness4 Apr. 1 at 12:35 PM
$FEMY It jeeps getting better. Huge progress as evidenced by steadily improving results.
0 · Reply
4RiskyBusiness4
4RiskyBusiness4 Apr. 1 at 12:25 PM
$FEMY Earnings improved by ~75%, signaling progress with streamlining distribution. Sales improved ~40% at the same time. These are material advancements and a strong signal that the market is prime for the company’s disruptive and patented portfolio in a ~$20B TAM. Eyes on the prize!
0 · Reply